Exchange: NASDAQ·Updated 07:58 PM EST
OTLK logo

OTLK Outlook Therapeutics Inc

$0.39
$0.011
(2.74%)
Today
Closed $0.39
$0.01
(2.56%)
After Hours
EarningsDec 18
Mkt Cap$94.94M
Vol5.2M

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
80

Extremely Bullish Sentiment

How do you feel about OTLK?

RZLV_MakesMeRich
$OTLK happy weekend y'all future holders. Just noticed my buy order .37 filled. Didn't even notice. Now I'm proud owner of 12.000 shares. Launch could be any day, even as soon as monday!
21
RZLV_MakesMeRich
$OTLK unfortunately, we had a lot of buyers but also a lot of sellers. It really suprises me, who sells an FDA approved product, 4-6 weeks (potentially even days) to US launch for the lowest price past approval? Just because it went up 4 cents a share? 🤣 It's alright, gotta get rid of those paper hands and we can go
1
21
adayxs
$OTLK Just checking in. Same old, same old. When I think it has settled out, I will buy more.
19
ALOSETE
$OTLK Without further dilution, a strengthened balance sheet through non-dilutive financing, and a successful commercial launch of LYTENAVA, I firmly believe we will break above $1. The upside potential is enormous if management delivers. 🚀
1
18
IniG
$OTLK "Piper Sandler has initiated coverage of Outlook Therapeutics Inc. ( NASDAQ:OTLK ) with an "Overweight" rating and a price target of $4.00. The stock is currently trading at $0.41, while the analysts' price target range is $1.60 to $10.50. Piper Sandler anticipates a significant shift from compounded and repackaged bevacizumab formulations to LYTENAVA. Feedback from a physician survey conducted by the research firm supports this assessment. Experts predict peak sales potential of at least $300 to $400 million for Lytenava in the US. Outlook Therapeutics currently has a market capitalization of approximately $88 million." This could be the reason for the recent pop. 🚀
21
Timerider
$OTLK Let United Healthcare get on board tonite and we open tomorrow at .82 Don't pinch pennies lads
20
Tom2772
$OTLK $KOD $EYPT Today, three words could start making the rounds in connection with the upcoming $OTLK U.S. launch 👀 PREFERRED – LYTENAVA – ANTHEM
1
19
Tom2772
$OTLK In my opinion, the current share price is an absolute joke considering all the recent developments. Hopefully, we’ll get the official U.S. launch announcement next week so that the company can finally start generating revenue. Happy weekend to all longs!
18
ALOSETE
$OTLK If Anthem confirms LYTENAVA’s preferred status in California, New York, Virginia, Ohio and Georgia, these five states represent approximately 27% of the US population, with a combined addressable market of around 587,000 bevacizumab injections annually. Potential first-year sales across these five states (all insurers), assuming a net price of $200 per vial: 5% market share: 29,350 vials — $5.9M. 10% market share: 58,700 vials — $11.7M. 20% market share: 117,400 vials — $23.5M. 30% market share: 176,100 vials — $35.2M.
21
bluenormas
$OTLK the Piper Sandler was a nice read, and the fact that they did it independently makes it more valid as far as them calling physicians. For me it's plain and simple. This is not a $.40 stock. They were already totally conservative on their estimates on how much they could sell just based on that it should be four bucks.
18
The_Claw
$OTLK Added at 36. Didn’t expect it would get this low and I’m taking the opportunity to build a nice position.
15
BigDaddyBritbox
$OTLK with the Anthem states now showing preferred, we very well could reach a breakeven point in 2027 on that alone. 
18
Timerider
$OTLK Pipers David Amsellem rated top 4% like BTIG Julian Harrison top 2% both 4 dollar targets 2027 Brains are important as are track records
17
Timerider
$OTLK Pipers David Amsellem is a 4.85 star analyst and Julian Harrison of BTIG is 4.98 They both are conservative with 4 dollar targets for 2027, not 10.50 Smarter than most in the pharma field reduces risk for we retailers
17
Tom2772
$OTLK Piper Sandler sees $300–400M in peak U.S. sales potential for LYTENAVA, based partly on its own survey of retina specialists. OTLK's own base case is even higher, over $500M in annual U.S. sales by 2030. Applying the average biotech EV/Forward Sales multiple of 3.6x gives us: $300M = $1.08B, $400M = $1.44B, and $500M = over $1.8B in implied valuation. And OTLK currently has a market cap of just around $97M. Even the lowest valuation scenario is more than 11 times OTLK's current market cap. That's remarkable in my opinion, especially when I look at other companies in the retinal space that already have Phase 3 clinical data but are still some time away from commercializing a product, yet command multi-billion-dollar valuations.
16
Simba00769
$OTLK This is truly a diamond in the sand, but as all growth names it needs patience. Congrats for the coverage initiation By Sandler. This will invite other industry analysts to look into it. Keeping my excitement moderated and slowly accumulating shares.
15
ALOSETE
$OTLK If UnitedHealthcare grants LYTENAVA preferred status, could we be looking at one of the biggest catalysts since FDA approval? I believe the market is significantly underestimating the potential impact of such a decision.
14
RZLV_MakesMeRich
$OTLK we might get to 40, 50, 60 cents. Or even a dollar. It's still cheap. I might consider selling some part of my investment once we cross $4!
1
12
sta120908
$OTLK 13GA filed by CVI Investment/Height Capital Management, reporting ownership: 21,000,000 warrants. Compared with their first 13G filed on 2026/8/19, CVI (1) sold 20,000,000 common shares, and (2) is now only holding 21,000,000 warrants. ===> So, who did CVI sell these 20,000,000 common shares to? CVI might have (1) used them to cover for the naked short or short done before 2026/8/13 public offering, or (2) sold them into public market/retailer investors, or (3) sold them to buyout bidders??
16
Mmc10
$OTLK .... institutional ownership has recently increased from 27% to 33%.... fingers crossed a positive sign for SP to come.
16

Advertisement|Remove ads.